title: Acromegaly.
abstract: Acromegaly is caused by growth hormone hypersecretion, mostly from a pituitary adenoma, driving insulin-like growth factor 1 overproduction. Manifestations include skeletal and soft tissue growth and deformities; and cardiac, respiratory, neuromuscular, endocrine, and metabolic complications. Increased morbidity and mortality require early and tight disease control. Surgery is the treatment of choice for microadenomas and well-defined intrasellar macroadenomas. Complete resection of large and invasive macroadenomas rarely is achieved; hence, their low rate of disease remission. Pharmacologic treatments, including long-acting somatostatin analogs, dopamine agonists, and growth hormone receptor antagonists, have assumed more importance in achieving biochemical and symptomatic disease control.
authors.affiliation: Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA, 90048, USA. benshlomoa@cshs.org
authors.forename: Anat
authors.initials: A
authors.lastname: Ben-Shlomo
authors.forename: Shlomo
authors.initials: S
authors.lastname: Melmed
mesh_terms: D000172:Acromegaly / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D004298:Dopamine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006727:Hormone Antagonists / Q000627:therapeutic use; D019382:Human Growth Hormone / Q000502:physiology; D006801:Humans; D010911:Pituitary Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy
chemical_list: D006727:Hormone Antagonists; D019382:Human Growth Hormone; D004298:Dopamine